Author Correction: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.

Autor: Herranz N; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Gallage S; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Metabolic Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Mellone M; Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton, UK., Wuestefeld T; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany.; Stem Cell & Regenerative Biology, Genome Institute of Singapore, Singapore, Singapore., Klotz S; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany., Hanley CJ; Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton, UK., Raguz S; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Acosta JC; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Innes AJ; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Banito A; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Georgilis A; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Montoya A; Proteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Wolter K; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany., Dharmalingam G; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Faull P; Proteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Carroll T; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Martínez-Barbera JP; Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London, UK., Cutillas P; Proteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK., Reisinger F; Institute for Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany., Heikenwalder M; Institute for Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany.; Division of Chronic Inflammation and Cancer, German Cancer Research (DKFZ), Heidelberg, Germany., Miller RA; Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, Michigan, USA., Withers D; Metabolic Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK., Zender L; Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany., Thomas GJ; Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton, UK., Gil J; Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK. jesus.gil@csc.mrc.ac.uk.; Epigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK. jesus.gil@csc.mrc.ac.uk.

Publikováno v: Nature cell biology [Nat Cell Biol] 2024 Jun; Vol. 26 (6), pp. 1019.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p.

Autor: Faure-Dupuy S; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany., Riedl T; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Rolland M; Laboratory of Molecular Immunology and Signal Transduction, GIGA-Institute, University of Liège, Liège, Belgium., Hizir Z; Laboratory of Molecular Immunology and Signal Transduction, GIGA-Institute, University of Liège, Liège, Belgium., Reisinger F; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Virology, Helmholtz Zentrum München, Munich, Germany., Neuhaus K; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Schuehle S; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Remouchamps C; Laboratory of Molecular Immunology and Signal Transduction, GIGA-Institute, University of Liège, Liège, Belgium., Gillet N; Integrated Veterinary Research Unit, Namur Research Institute for Life Sciences, Namur, Belgium., Schönung M; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.; Section Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany., Stadler M; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Wettengel J; Institute of Virology, Helmholtz Zentrum München, Munich, Germany., Barnault R; INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France., Parent R; INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France., Schuster LC; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany., Farhat R; INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France., Prokosch S; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Leuchtenberger C; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Öllinger R; Institute of Molecular Oncology and Functional Genomics, Rechts der Isar University Hospital, Munich, Germany., Engleitner T; Institute of Molecular Oncology and Functional Genomics, Rechts der Isar University Hospital, Munich, Germany., Rippe K; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany., Rad R; Institute of Molecular Oncology and Functional Genomics, Rechts der Isar University Hospital, Munich, Germany., Unger K; Research Unit of Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany., Tscharahganeh D; Helmholtz-University Group 'Cell Plasticity and Epigenetic Remodeling', German Cancer Research Center (DKFZ) and Institute of Pathology University Hospital, Heidelberg, Germany., Lipka DB; Section Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Faculty of Medicine, Otto-von-Guericke-University, Magdeburg, Germany., Protzer U; Institute of Virology, Helmholtz Zentrum München, Munich, Germany., Durantel D; INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France., Lucifora J; INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France., Dejardin E; Laboratory of Molecular Immunology and Signal Transduction, GIGA-Institute, University of Liège, Liège, Belgium., Heikenwälder M; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.

Publikováno v: JHEP reports : innovation in hepatology [JHEP Rep] 2021 Aug 25; Vol. 3 (6), pp. 100354. Date of Electronic Publication: 2021 Aug 25 (Print Publication: 2021).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Mechanisms underlying the compromised clinical efficacy of interferon in clearing HBV.

Autor: Lei, Zhuoyan¹ (AUTHOR), Wang, Luye¹ (AUTHOR), Gao, Hanlin¹ (AUTHOR), Guo, Shubian¹ (AUTHOR), Kang, Xinjian¹ (AUTHOR), Yuan, Jiajun¹ (AUTHOR), Lv, Ziying¹ (AUTHOR), Jiang, Yuxin¹ (AUTHOR), Yi, Jinping² (AUTHOR), Chen, Zhi³ (AUTHOR), Wang, Gang¹ (AUTHOR) wg008@zjsru.edu.cn

Publikováno v: Virology Journal. 12/4/2024, Vol. 21 Issue 1, p1-13. 13p.